Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS)

References

• Apiquian R, Córdoba R, Lauzã M. 2010. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat 7:19–26.
   PubMed Web of Science ®Google Scholar
• Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M, Persson U. 2012. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after initiation of risperidone long-acting injection. Schizophr Res Treatment 2012:791468.
   PubMedGoogle Scholar
• Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. 2011. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25:567–620.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93.
   PubMed Web of Science ®Google Scholar
• Cañas F, Möller HJ. 2010. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin Drug Saf 9:683–697.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Kempton MJ, Rosenheck RA. 2013. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28:57–66.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. 2010. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35:2367–2377.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. 2012. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia?Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 134:187–194.
   PubMed Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. 2003. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 416:16–23.
   PubMedGoogle Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Genthoj B, Gattaz WF, et al. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14:2–44.
   PubMed Web of Science ®Google Scholar
• Hong J, Novick D, Brugnoli R, Karagianis J, Dossenbach M, Haro JM. 2012. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. BMC Psychiatry 12:218.
   Google Scholar
• Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, et al. 2009. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33:1022–1031.
   PubMed Web of Science ®Google Scholar
• Kemp R, Kirov G, Everitt B, Hayward P, David A. 1998. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 172:413–419.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. 2013. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74: 568–575.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. 2014. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40: 192–213.
   PubMed Web of Science ®Google Scholar
• Lambert T, Emmerson B, Hustig H, Resseler S, Jacobs A, Butcher B, et al. 2012. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry 12:25.
   Google Scholar
• Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, et al. 2010. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv 61:1239–1247.
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. 2011. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83–92.
   PubMed Web of Science ®Google Scholar
• Macfadden W, DeSouza C, Crivera C, Kozma CM, Dirani RD, Mao L, et al. 2011. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry 11:167.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. 2009. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287–296.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, et al. 2010. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 26:501–509.
   PubMed Web of Science ®Google Scholar
• Risperdal® Consta® prescribing information, 2012. Available from: http://www.janssencns.com/risperdal/risperdal-prescribing-information.
   Google Scholar
• Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. and the CSP555 Research Group. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 364:842–851.
   PubMed Web of Science ®Google Scholar
• Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Álamo C. 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51:531–539.
   PubMed Web of Science ®Google Scholar
• Schwartz RC. 2007. Concurrent validity of the Global Assessment of Functioning Scale for clients with schizophrenia. Psychol Rep 100:571–574.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609.
   PubMed Web of Science ®Google Scholar
• Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso CM, et al. 2010. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res 118:271–278.
   PubMed Web of Science ®Google Scholar